2022 Fiscal Year Final Research Report
Elucidation of glycosyltransferase-mediated regulatory mechanism of diabetes-cancer relationship and therapeutic strategy
| Project/Area Number |
20K08344
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Osaka Medical and Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
朝日 通雄 大阪医科薬科大学, 医学部, 教授 (10397614)
三善 英知 大阪大学, 大学院医学系研究科, 教授 (20322183)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 糖転移酵素 / O-GlcNAc修飾 / コアフコース修飾 / 糖尿病合併癌 |
|---|
| Outline of Final Research Achievements |
We examined the effect of O-GlcNAc or core-fucose modification that is known to increase in patients with diabetes on cancer cell proliferation or metastasis. We found that augmented O-GlcNAcylation in cancer microenvironment promoted cancer metastasis and augmented core-fucosylation in the microenvironment promoted cancer growth. Since the fact that diabetes is one of the poor prognostic factors may be partly due to augmentation of O-GlcNAcylation or core-fucosylation, those modifications could become drug targets for cancer patients with diabetes.
|
| Free Research Field |
消化器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
糖鎖修飾であるO-GlcNAc修飾やコアフコース修飾は糖尿病で亢進することが知られている。糖尿病は、独立した癌のリスクや予後増悪因子であるが、O-GlcNAc修飾やコアフコース修飾の亢進がそのメカニズムの一端を担っていると考えられる。糖尿病担癌患者の治療戦略の一つとして、O-GlcNAc修飾やコアフコース修飾を標的とした糖鎖改変治療が有望である可能性が示唆された。
|
